Affimed (AFMD) to Release Earnings on Wednesday

Affimed (NASDAQ:AFMD) will be issuing its quarterly earnings data before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Affimed (NASDAQ:AFMD) last released its quarterly earnings data on Wednesday, May 22nd. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.19. Affimed had a negative return on equity of 23.61% and a negative net margin of 29.04%. The company had revenue of $12.89 million during the quarter, compared to the consensus estimate of $6.77 million. On average, analysts expect Affimed to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ AFMD traded down $0.01 during trading hours on Tuesday, hitting $2.68. The company’s stock had a trading volume of 36,927 shares, compared to its average volume of 691,952. Affimed has a 12 month low of $1.40 and a 12 month high of $7.35. The stock has a 50 day moving average price of $3.01. The company has a market capitalization of $184.68 million, a P/E ratio of -7.05 and a beta of 2.84. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.16 and a current ratio of 3.17.

AFMD has been the subject of several research analyst reports. Laidlaw set a $10.00 price objective on Affimed and gave the stock a “buy” rating in a report on Wednesday, July 3rd. Zacks Investment Research upgraded Affimed from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research note on Tuesday, July 2nd. Finally, ValuEngine downgraded Affimed from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Affimed currently has a consensus rating of “Buy” and a consensus target price of $5.63.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Further Reading: What are the most popular ETFs

Earnings History for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with's FREE daily email newsletter.